H.R. 4482 · 115th Congress
Opioid Abuse Deterrence, Research, and Recovery Act of 2017
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 115th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
MeadowsSponsor2 cosponsors · 2 R
1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill amends the Controlled Substances Act to prohibit the Drug Enforcement Administration from registering, or renewing the registration of, a practitioner who is licensed to prescribe opioids in schedule II or III unless the practitioner agrees to limit an opioid prescription for the initial treatment of acute pain to the lesser of a seven-day supply…
What it does: CRS summary · Introduced in House · Nov 29, 2017
Opioid Abuse Deterrence, Research, and Recovery Act of 2017
This bill amends the Controlled Substances Act to prohibit the Drug Enforcement Administration from registering, or renewing the registration of, a practitioner who is licensed to prescribe opioids in schedule II or III unless the practitioner agrees to limit an opioid prescription for the initial treatment of acute pain to the lesser of a seven-day supply (no refill) or an opioid prescription limit established under state law.
Certain opioid prescriptions are not subject to the limit (e.g., an opioid that is approved and prescribed for the treatment of an opioid use disorder).
The Food and Drug Administration (FDA) must continue to work with stakeholders to promote the development of abuse-deterrent opioid formulations.
The bill requires: (1) the Government Accountability Office to study and report on health care policy changes that may have contributed to the increase in opioid overdoses and deaths, and (2) the FDA to study the feasibility of replacing opioid prescribing limits established by this bill with evidence-based clinical guidelines for opioid prescribing.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Opioid Abuse Deterrence, Research, and Recovery Act of 2017
Latest action (Jan 9, 2018): Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Policy area: Crime and Law Enforcement · Origin: House · Introduced: Nov 29, 2017
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.